Canadian grants & funding programs

Mentoring Networks to Enhance Diversity in NIDCD's Extramural Research Workforce (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Mentoring Activities

United States

Enabling Accessibility Fund – Small projects

75% funding for accessibility projects, enhancing community participation and employment opportunities.

This funding opportunity aims to make communities and workplaces across Canada more accessible for persons with disabilities. It will fund projects that create more opportunities for persons with disabilities to take part in community activities, programs, and services, and access employment.

Canada

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

United States

Research on Interventions that Promote the Careers of Individuals in the Biomedical Research Enterprise (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages solicits applications that propose research designed to test training, mentoring, and networking interventions intended to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the design and implementation of potential interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.

United States

Idea to Innovation Grants

75% funding for technology validation, market studies, and prototype development.

I2I grants accelerate the pre-competitive development of promising technology from the university and college sector, and promote its transfer to a new or established Canadian company.

Canada

FCM – Safe and Active School Routes: access up to $125,000.

50% funding for active transportation infrastructure, safety features, and community engagement

# Safe and Active School Routes Grant ## Grant Goals - Increase walking, biking, and rolling to school - Improve active transportation infrastructure and road safety - Reduce greenhouse gas emissions through mode shift - Support community capacity building in transportation planning - Enhance child and youth safety in transportation networks ## Keywords - Active transportation - School route infrastructure - Sustainable mobility - Pedestrian safety - Cycling infrastructure - Transportation equity - Climate action - Youth mobility - Urban design - Traffic calming - Multimodal transportation - Community engagement - Infrastructure resilience - Green infrastructure - Accessibility design - Reconciliation-focused planning - Low-carbon transportation - Neighborhood connectivity - Safe routes - Student transportation ## Description The Safe and Active School Routes grant provides funding and peer learning support for municipalities to develop infrastructure that enables students to safely walk, bike, or roll to school. The program focuses on creating low-emission transportation solutions that improve community mobility and child safety. ## Target Audience - Canadian municipal governments - Local government transit agencies - Indigenous communities (with municipal partnerships) - Municipalities of all sizes - Transportation planners - Urban designers - School district administrators - Community development professionals ## Eligible Expenses - Active transportation infrastructure design - Quick-build installations - Pathway and sidewalk construction - Bicycle lane development - Intersection safety improvements - Road safety enhancements - Infrastructure quality upgrades - Supportive infrastructure (lighting, signage, storage) ## Eligibility - Canadian municipal entities - Projects targeting primary/secondary school routes - Demonstrable potential for student transportation mode shift - Proven municipal commitment to project - Jurisdiction or permission over project area - Partnership with school administration ## Criteria - Improve active transportation user safety - Connect to existing transportation networks - Consider accessibility - Multidisciplinary team involvement - Collaboration with implementation partners - Innovative approach demonstration - Youth participation - Equity-focused design - Reconciliation principles integration ## Program Requirements - Identify specific school route(s) - Demonstrate student transportation impact - Provide school partnership proof - Establish jurisdiction/permission - Align with municipal strategic plans - Potential for greenhouse gas reduction - Commit to peer learning program participation ## Hiring Criteria - Multidisciplinary team representation - Cross-sector collaboration skills - Transportation planning expertise - Climate action understanding - Community engagement capabilities - Equity and inclusion awareness - Innovation mindset ## Due Dates - Pre-application deadline: October 17, 2025 - Application intake: Mid-summer 2025 ## Start Dates - Varies based on project approval - Typically within 6 months of application submission ## Age Requirements - Focus on primary and secondary school-aged children - No specific applicant age restrictions ## Industry / Area of Work - Municipal transportation - Urban planning - Climate action - Education infrastructure - Community development - Sustainable mobility - Youth engagement

Alberta · British Columbia · Manitoba · New Brunswick +9 more

Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)

The purpose of this limited competition R00 program is to provide physician scientists in blood science with a seamless pathway from a mentored K99/R00 award to investigator independence. Eligible applicants will have matriculated through the Career Pathway to Independence in Blood Science Awards for Physician Scientists ( K99/R00) program for up to three, but no more than five years. The strongest R00 applicants will propose an updated, well-conceived plan for 23 years of independent research support intended to prepare the applicant to subsequently compete for an R01 or equivalent award. These research projects are limited to those that fall within the Division of Blood Diseases and Resources mission. The NIH encourages institutions to recruit and retain individuals from groups currently underrepresented in the biomedical sciences, and to enhance the diversity of the clinician-investigator workforce (NOT-OD-15-053).

United States

Innovation Assistance Program (IAP)

Provides financial support for research and development projects, technology validation, and commercialization activities. Covers up to 80% of eligible project costs.

Canada

Development program – Prequalified stream

50% funding for script development, project packaging, and talent support.

The Development Program finances Canadian feature films at the development stage. Starting in the summer of 2024, Telefilm will be launching a pilot initiative called the Springboard Initiative.

Canada

OMIF – Live Music

50% funding for live music events, festivals, and artist promotions in Ontario.

The OMIF Live Music stream supports businesses and organizations that produce or promote live music events featuring Canadian artists, including eligible music festivals and concert series.

Ontario

NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Independent Clinical Trial Not Allowed)

The purpose of the Research and Entrepreneurial Development Immersion (REDI): NIA Entrepreneurship Enhancement Award (R25) is to promote the development of entrepreneurial training programs that are designed to broaden the skillset of graduate students and postdocs, as well as early career master's, Ph.D., and Dr.P.H. scientists, in fields relevant to the mission of NIA, including aging and Alzheimer's disease (AD) research. The goal of this program is to prepare trainees for a wide range of career paths, including those that are outside the normal research environment.

United States

STrengthening Research Opportunities for NIH Grants (STRONG): Structured Institutional Needs Assessment and Action Plan Development for Resource Limited Institutions (RLIs) (UC2 - Clinical Trial Not Allowed)

The Strengthening Research opportunities for NIH grants: STrengthening Research Opportunities for NIH Grants (STRONG): STRONG-RLI program will support research capacity needs assessments by eligible Resource Limited Institutions (RLIs). The program will also support the grantee institutions to use the results of the assessments to develop action plans for how to meet the identified needs.. RLIs are defined as institutions with a mission to serve historically underrepresented populations in biomedical research that award degrees in the health professions (and in STEM fields and social and behavioral sciences) and have received an average of 0 to $25 million per year (total cost) of NIH Research Project Grant (RPG) support for the past three fiscal years.

United States

Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences

United States

India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed)

This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications. Areas of Research Collaboration: Applications are encouraged from organization/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collaborations with Indian investigators on the following: diabetic retinopathy, glaucoma, age-related macular degeneration, retinitis pigmentosa, including rare and genetic diseases such as congenital cataracts, as well as other eye conditions such as ocular inflammation/uveitis, refractive error, low vision, and corneal injury. Basic, translational, or epidemiological research maybe proposed. Clinical trials will not be supported under this FOA.

United States

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

United States

BRAIN Initiative-Related Research Education: Short Courses (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in research areas relevant to the BRAIN Initiative. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences. The purpose of this FOA is to encourage applications for the continuation and/or expansion of ongoing and new research education programs that will significantly advance the educational goals of the BRAIN Initiative as described in BRAIN 2025: A Scientific Vision including neuroethics and opportunities to increase the workforce diversity in BRAIN Initiative research areas. Proposed programs are expected to offer hands-on research experiences, an in-depth conceptual understanding of the techniques and tools employed, and the knowledge to apply appropriate analytic approaches to the resulting data. Participants are limited to undergraduate, graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty with an emphasis on diversity as defined by NIH (NOT-OD-20-031). Proposed programs will facilitate the development of a sophisticated cadre of future investigators with the knowledge and skills to apply BRAIN Initiative techniques and approaches and data resources (BRAIN cell census data https://bicon.org/data) to research questions about brain function and behavior. Programs appropriate for this FOA must include participants from a regionally/nationally recruited cohort.

United States

NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)

The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness to ensure the research is scalable, reproducible, and generalizable. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable approaches to discovery, curation, analysis, organization, and management of health-related data and digital objects.

United States

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

United States

NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)

The NIH Director's Early Independence Award supports rigorous and promising junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations, are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

United States

Integrating Health Disparities into Immuno-Oncology (HDIO) (P20 Clinical Trial Not Allowed)

The scientific objectives of this P20 FOA are to support planning and feasibility studies to integrate cancer health disparities into immuno-oncology research studies. The P20 project will enable complementary, multi-disciplinary research teams to address inter-disciplinary research to integrate cancer health disparities into immuno-oncology research. It is anticipated these feasibility or pilot studies will support the exploration of novel or high-risk research hypotheses.

United States

Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

United States

Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (ESI) (R35 - Clinical Trial Optional)

The Maximizing Investigators' Research Award (MIRA) under this Notice of Funding Opportunity (NOFO) provides support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this NOFO, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding.

United States

Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences

United States

Manitoba First Nation Business Support Program

I couldn't find specific details about the percentage of funding or the eligible expenses directly from the provided links. Therefore, I cannot create an accurate tagline based on the grant's actual offerings. If you have more specific information about the grant, I can help you craft a tagline.

This program offers non-repayable funding of up to 75% of costs to a maximum of $20,000 to assist in the research and development of a quality business plan.

Manitoba

Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)

The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows applications from eligible NIGMS-funded investigators and from New Investigators proposing research within the scientific mission of NIGMS. The FOA also allows renewal applications from all current MIRA grantees (established investigators and those previously funded as early-stage investigators). PD/PIs who are currently Early Stage Investigators (ESIs) should apply through the ESI MIRA FOA and should not apply through this FOA.

United States

NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

United States

Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed)

The NINDS Materials to Enhance Training in Experimental Rigor (METER) UE5 will support curriculum development in the form of innovative educational materials that will be incorporated into a new cutting-edge online resource that aims to promote awareness, understanding, and practice of fundamental principles of rigorous biomedical research for researchers and other scientists in various career stages and learning environments. This UE5 FOA runs in parallel with a companion UC2 FOA that solicits applications for the NINDS center for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), described in detail in RFA-NS-21-009.

United States

Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)

NLM wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.

United States

Industry Commercialization Associates Program – Alberta Innovates

Up to 75% funding for employee salaries, driving commercialization and innovation growth.

Alberta Innovates’ Industry Commercialization Associates Program offsets a portion of costs related to hiring an associate to perform technical commercialization activities. Contribution is paid as a monthly stipend plus an annual Expense Allowance of up to $7,000 to cover a portion of non-salary costs incurred by the researcher. Associates may be hired as a part-time or full-time employee.

Alberta

OCI - Talentedge

A funding program that provides financial assistance to small and medium-sized enterprises (SMEs) in Ontario to help them develop innovative technologies and products related to advanced manufacturing and materials. The Talentedge program is administered by the OCE, an organization that supports the growth and development of innovative businesses in Ontario..

Ontario

Alberta Innovates – Industry R&D Partnerships

Cost-shared funding for R&D, prototyping, and technology adoption.

Support for SMEs to collaborate with researchers and adopt new technologies; ongoing intake for certain programs.

Alberta

POR Awards – Transition to Leadership Stream – Phase 2

Up to 50% for expenses related to social impact work

The Strategy for Patient-Oriented Research (SPOR) is a national coalition of federal, provincial and territorial partners (patients and informal caregivers, health authorities, academic health centres, charities, philanthropic organizations, private sector, etc.) dedicated to the integration of research into care.. . Patient-oriented research, which is foundational to evidence-informed health care, refers to a continuum of research that engages patients as partners, focusses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with relevant stakeholders, aims to apply the knowledge generated to improve healthcare systems and practices.. . The vision for SPOR is that Canada will demonstrably improve health outcomes and enhance the health care experience for patients through the integration of evidence at all levels of the health care system. The CIHR Strategic Plan 2021-2031 sets a vision of best health for all, powered by outstanding research. Through the objectives of this funding opportunity and the application of a patient-oriented research approach, SPOR will contribute to the acceleration of several CIHR Strategic Plan priorities, more specifically Priority B: Strengthen Canadian Health Research Capacity; Priority C: Accelerate the Self-Determination of Indigenous Peoples in Health Research; and Priority E: Integrate Evidence in Health Decisions.

Canada

Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research for people who use drugs. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons living with HIV.

United States

New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional )

This funding opportunity announcement will support the development and testing of enhanced models of care that are able to optimally integrate HIV, addiction, and primary care services.

United States

Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites early-stage physicians and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research.NIA is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.

United States

Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research.The National Institute on Aging (NIA) is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.

United States

Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) pre-trial feasibility and acceptability testing of services and service system research relevant to the prevention of substance use. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through FOA include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.

United States

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)

The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

United States

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)

As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services

United States

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials to test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. The subsequent larger trial should have the potential to make a significant impact on public health.

United States

NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)

NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

United States

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.

United States

Leveraging Social Networks to Promote Widespread Individual Behavior Change (R34 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) invites R34 applications to support the planning activities necessary to develop social network interventions to promote health across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (such as populations in mid- and late-life). Applications suited to this R34 will focus on planning activities for social network interventions for which a target interpersonal process of behavior change or social network characteristic has already been identified. Planning activities are those activities that are expected to yield necessary and sufficient information to inform final decisions about a social network health behavior change intervention prior to instigation of a hypothesis-driven trial to test a social network intervention. Activities may include (but are not limited to) team-building, protocol development, piloting of systems for data collection and/or management, feasibility and acceptability testing, staff training, and establishing documentation procedures. . Basic experimental and observational behavioral and/or social science applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks are outside the scope of this RFA. Research to identify targets for future social network health behavior change interventions and/or to develop, refine, or optimize measures (assays) of putative targets are also outside the scope of this RFA. Both of these types of research are most appropriate for the companion R01 RFA (RFA-AG-24-025). . Projects that propose to test the efficacy or effectiveness of a social network health behavior change intervention are also outside the scope of this RFA, which focuses only on pre-trial planning and development activities.

United States

Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)

Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial not allowed)

United States

NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

Reissue of PAR-19-155

United States

ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed)

NIH established a clinical genomics infrastructure to develop an openly accessible knowledgebase that promotes data sharing and provides standardized infrastructure and tools for determining the clinical relevance of genetic variants through two initiatives: the Clinical Genomics Resource (ClinGen) and the Clinical Variant Database (ClinVar) of clinical variation. ClinGen defines the clinical relevance of genes and variants for use in precision medicine and research by standardizing clinical annotation and interpretation of variants and implementing evidence-based expert consensus assertions. The purpose of this Notice of Funding Opportunity (NOFO) is to establish Expert Panels that will select genes and genomic variants associated with diseases or conditions of high priority to participating NIH Institutes and Centers (ICs) and systematically determine their clinical significance for diagnosis and treatment of these diseases or conditions. The Genomic Curation Expert Panels funded through this NOFO are required to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar procedures, interfaces, tools, and informatics infrastructure.

United States

Limited Competition for the NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

United States

Industry R&D Associates Program – Alberta Innovates

Up to 75% funding for salaries, R&D expertise, and innovative tech development.

Alberta Innovates’ Industry R&D Associates Program offsets a portion of costs related to hiring an associate to perform technical research and development activities. Contribution is paid as a monthly stipend plus an annual Expense Allowance of up to $7,000 to cover a portion of non-salary costs incurred by the researcher. Associates must be hired as a full-time employee.

Alberta